Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery

Summary

Surgeons consider the benefit-to-harm ratio when making decisions regarding the use of anticoagulant venous thromboembolism (VTE) prophylaxis. We evaluated the benefit-to-harm ratio of the use of newer anticoagulants as thromboprophylaxis in patients undergoing major orthopaedic surgery using the likelihood of being helped or harmed (LHH), and assessed the effects of variation in the definition of major bleeding on the results. A systematic literature search was performed to identify phase II and phase III studies that compared regulatory authority-approved newer anticoagulants to the low-molecularweight heparin enoxaparin in patients undergoing major orthopaedic surgery. Analysis of outcomes data estimated the clinical benefit (number-needed-to-treat [NNT] to prevent one symptomatic VTE) and clinical harm (number-needed-to-harm [NNH] or the NNT to cause one major bleeding event) of therapies. We estimated each trial’s benefitto-harm ratio from NNT and NNH values, and expressed this as LHH = (1/NNT)/(1/NNH) = NNH/NNT. Based on reporting of efficacy and safety outcomes, most studies favoured enoxaparin over fondaparinux, and rivaroxaban over enoxaparin. However, when using the LHH metric, most trials favoured enoxaparin over both fondaparinux and rivaroxaban when they included surgical-site bleeding that did not require reoperation in the definition of major bleeding. The exclusion of bleeding at surgical site which did not require reoperation shifted the benefit-to-harm ratio in favour of the newer agents. Variations in the definitions of major bleeding may change the benefit-to-harm ratio and subsequently affect its interpretation. Clinical trials should attempt to improve the consistency of major bleeding reporting.

Keywords

Major orthopaedic surgery - thromboprophylaxis - enoxaparin - the likelihood of being helped or harmed - benefit-to-harm ratio

• References

• 1 Falck-Ytter Y, Francis CW, Johanson NA. et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 278S-325S.
• 2 Eriksson BI, Borris LC, Dahl OE. et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
• 3 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
• 4 Kakkar AK, Brenner B, Dahl OE. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
• 5 Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
• 6 Turpie AG, Lassen MR, Davidson BL. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
• 7 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxapa-rin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
• 8 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
• 9 RE-MOBILIZE Writing Committee. Ginsberg JS, Davidson BL. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
• 10 Eriksson BI, Dahl OE, Huo MH. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-729.
• 11 Lassen MR, Raskob GE, Gallus A. et al. Apixaban or enoxaparin for thrombo-prophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
• 12 Lassen MR, Raskob GE, Gallus A. et al. Apixaban versus enoxaparin for throm-boprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial. Lancet 2010; 375: 807-815.
• 13 Lassen MR, Gallus A, Raskob GE. et al. Apixaban versus enoxaparin for throm-boprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
• 14 Eichler HG, Abadie E, Raine JM. et al. Safe drugs and the cost of good intentions. N Engl J Med 2009; 360: 1378-1380.
• 15 Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009; 15: 377-388.
• 16 Hull RD, Yusen RD, Bergqvist D. Variation in major bleeding definitions in phase III orthopedic VTE prophylaxis trials and the impact on major bleeding frequency. J Thromb Haemost. 2009 7. (Suppl 2): Abstract OC-TU-021.
• 17 Ng HJ, Crowther MA. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006; 43 (01) (Suppl. 01) S77-S83.
• 18 Schulman S, Beyth RJ, Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 257S-298S.
• 19 FDA Advisory Committee Briefing Document.. Cardiovascular and Renal Drugs Advisory Committee. March 19, 2009. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/09/briefing/2009-4418b1-01-FDA.pdf. Accessed April 30, 2013.
• 20 Bayer Inc., Toronto, ON, Canada.. Product monograph Xarelto (rivaroxaban tablet). revised April 12, 2013. Available at: http://www.bayer.ca/files/Xarelto%20English%2012APR2013.pdf?#. Accessed April 30, 2013.
• 21 Boehringer Ingelheim Canada Ltd., Burlington, ON, Canada.. Product monograph Pradax (dabigatran etexilate capsules). revised January 27, 2012. Available at: http://www.boehringer-ingelheim.ca/en/Home/Human_HealthOur_Products/Product_Monographs/Pradax-pm.pdf. Accessed April 30, 2013.
• 22 GlaxoSmithKline Inc., Mississauga, ON, Canada.. Product monograph Arixtra (fondaparinux sodium injection) revised June 7, 2012. Available at: http://www.gsk.ca/english/docs-pdf/product-monographs/Arixtra.pdf. Accessed April 30, 2013.
• 23 Canadian Agency for Drugs and Technologies in Health.. Dabigatran or riva-roxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. Available at: http://www.cadth.ca/en/products/health-technology-assessment/publication/908. Accessed April 30, 2013.
• 24 Battaggia A, Vaona A. ARR, NNT, NNH, LLH... Maestro, il senso lor me duro! (Master, these words import hard meaning!). Available at: http://rivistaqq.org/wp/wp-content/uploads/qq23En.pdf. Accessed April 30, 2013.
• 25 Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013; 67: 407-411.
• 26 Akobeng AK. Communicating the benefits and harms of treatments. Arch Dis Child 2008; 93: 710-713.
• 27 Moher D, Liberati A, Tetzlaff J. et al. The PRISMA Group. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 21: 6 e1000097.
• 28 Turpie AG, Bauer KA, Eriksson BI. et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
• 29 Lassen M. Pooled analysis of two randomized studies comparing fondaparinux 2.5 mg and enoxaparin 40 mg for preventing venous thromboembolism (VTE) in hip surgery using new study endpoints. J Thromb Haemost. 2009 7. (Suppl 2): Abstract PP-WE-454.
• 30 Lassen MR, Bauer KA, Eriksson BI. et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
• 31 Eriksson BI, Bauer KA, Lassen MR. et al. Fondaparinux compared with enox-aparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-1304.
• 32 Bauer KA, Eriksson BI, Lassen MR. et al. Fondaparinux compared with enox-aparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
• 33 European Medicines Agency.. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk, 15 November 2007. Available at: http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf. Accessed April 30, 2013.
• 34 Dahl OE, Quinlan DJ, Bergqvist D. et al. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 2010; 8: 1966-1975.
• 35 Pitrou I, Boutron I, Ahmad N. et al. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169: 1756-1761.
• 36 Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009; 169: 1737-1739.
• 37 Quinlan DJ, Eikelboom JW, Goodman SG. et al. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J 2011; 32: 2256-2265.
• 38 Eikelboom JW, Quinlan DJ, O’Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120: 2006-2011.
• 39 Hull RD, Liang J, Brant R. Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled. Thromb Res 2010; 126: 164-165.
• 40 Van Thiel D, Kalodiki E, Wahi R. et al. Interpretation of benefit-risk of enoxapa-rin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009; 15: 389-394.
• 41 Longo UG, Maffulli N, Denaro V. Correspondence: rivaroxaban versus enox-aparin after total knee arthroplasty. Lancet 2009; 374: 681-682.
• 42 Raju NC, Dimmitt S, Eikelboom JW. Correspondence: rivaroxaban versus enox-aparin after total knee arthroplasty. Lancet 2009; 374: 681-682.
• 43 Stief T. Correspondence: rivaroxaban versus enoxaparin after total knee arthro- plasty. Lancet 2009; 374: 681-682.
• 44 Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A. et al. Correspondence: rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet 2009; 374: 681-682.
• 45 Turpie AG, Jamal W, Schmidt A. et al. XAMOS: A non-interventional study comparing oral rivaroxaban with conventional regimens for thromboprophyla-xis after major orthopaedic surgery of the hip and knee. Br J Haematol 2012; 157 (Suppl. 01) 9-10.